Genvax Technologies

What Genvax Technologies does

Genvax Technologies is an early-stage animal health biotechnology company developing next-generation mRNA and nanoparticle vaccines for livestock. Founded in February 2021 in Ames, Iowa by Joel Harris and Dr. Hank Harris — who previously built and sold Harrisvaccines to Merck Animal Health in 2015 — the company is engineering a vaccine platform that combines mRNA technology with nanoparticle delivery systems, with stated capabilities for rapid variant updating, custom and herd-specific formulations, and scalable manufacturing at lower cost than incumbents.

The platform targets prevention and treatment of animal diseases in cattle, swine, and poultry, with an emphasis on rapid response to foreign animal disease outbreaks that threaten the U.S. food supply. Genvax is currently pursuing USDA approval for its vaccine candidates, a gating regulatory milestone before any commercial sale. Its product offering centers on two core lines: the mRNA plus nanoparticle vaccine development platform itself, and RNA vaccines for animal health applications tailored to livestock disease preparedness.

Commercially, Genvax operates a sales-led B2B go-to-market targeting livestock producers, veterinarians, and animal health organizations through direct engagement and strategic partnerships rather than traditional distribution channels. The company is pre-revenue, with cumulative funding of approximately $10 million-plus across a 2022 seed round, a 2024 SEC-registered exempt offering, and an oversubscribed Series Seed Plus in February 2025 led by United Animal Health. Genvax is incorporated in Delaware, headquartered at 2503 S. Loop Drive in Ames, Iowa, and restricts its website's use to persons in the United States and non-EU/non-EEA countries. Leadership comprises a small, experienced team including a CEO, Co-Founder, recently appointed CSO, and VPs of R&D and Regulatory Affairs.

Name

Genvax Technologies

Legal name

Genvax Technologies, Inc.

Website

https://genvax.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Genvax Technologies is an Ames, Iowa-based startup developing mRNA and nanoparticle vaccines for livestock disease prevention and rapid response to foreign animal disease outbreaks. Founded in 2021, the company serves U.S. livestock producers, veterinarians, and animal health organizations while pursuing USDA approval.

Ownership category

akta.pro rank

Product category

Veterinary Biologics / Animal Health Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH)

akta.pro secondary industries

Veterinary Vaccines (Biologics) (HLAMAEAL), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB), Autogenous (Herd-Specific) Vaccines (HLAMAKAF), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)

Keywords

• Animal vaccines
• MRNA livestock vaccines
• Nanoparticle vaccine platform
• Veterinary biologics
• Livestock disease prevention

Headquarters

HQ city

Ames

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Vaccine Sales: Revenue generation through sale of mRNA and nanoparticle vaccines for livestock and animal health applications to producers, veterinarians, and animal health organizations

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Genvax Technologies develops next-generation mRNA and nanoparticle vaccines for livestock and animal health applications. The company's platform enables rapid variant updating, custom and herd-specific vaccine formulations, and scalable manufacturing, with a focus on rapid response to foreign animal disease outbreaks affecting cattle, swine, and poultry. Vaccines are in development and pursuing USDA regulatory approval.

Product overview

Genvax Technologies offers a unified vaccine development platform centered on mRNA and nanoparticle technologies for animal health applications. The core platform enables rapid development of custom and herd-specific RNA vaccines for livestock, with a focus on foreign animal disease preparedness and rapid variant updating capabilities. The company is pursuing USDA approval for its vaccine candidates and operates from its Ames, Iowa headquarters.

Differentiator

Problem solved

Functional benefit

Products and services

• RNA Vaccines for Animal Health

Quantifiable outcome

• Lower manufacturing cost without bottlenecking manufacturing steps

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Zoetis: The world's largest animal health company with a broad portfolio of livestock and companion animal vaccines. Comparable as an incumbent competitor whose product set and global commercial footprint Genvax would have to compete with or partner into upon USDA approval.
• Huvepharma: Animal health and nutrition company with a livestock vaccines and biologics portfolio. Comparable as an incumbent in the same producer-driven sales channel Genvax must access to commercialize its USDA-approved vaccines.
• Phibro Animal Health: Diversified animal health and nutrition company serving livestock producers with vaccines and pharmaceuticals. Comparable as a broad incumbent whose sales force and producer relationships Genvax would have to build or partner around.
• Merck Animal Health: Major animal health incumbent and prior acquirer of Harrisvaccines (the founders' previous company). Directly relevant as a benchmark for the founders' prior exit path and as the dominant livestock vaccine franchise Genvax must displace or partner with.
• Elanco Animal Health: Public animal health company with substantial livestock and poultry vaccine franchises. Comparable as a broad incumbent whose vaccine portfolio competes for the same livestock producer budgets and veterinary channel relationships Genvax targets.
• Ceva Santé Animale: Global animal health company with a sizable livestock vaccine portfolio across poultry, swine, and ruminants. Comparable as a broad incumbent competing for the same foreign animal disease preparedness and livestock vaccination budgets.
• Boehringer Ingelheim Animal Health: Top-tier global animal health player with a strong livestock vaccine portfolio (e.g., Ingelvac, Enterisol). Comparable as a broad incumbent competitor and a likely strategic acquirer of differentiated platforms like Genvax's.

Direct peers

• Medgene Labs: Emerging U.S. animal vaccine company focused on rapid-response vaccine technology for livestock, including emerging disease outbreaks. Comparable to Genvax in stage, U.S. footprint, and platform-based rapid-response positioning against FAD outbreaks.
• Vaxxinova: Animal health vaccine company specializing in autogenous and licensed livestock vaccines, including a strong autogenous/custom-herd business. Highly comparable to Genvax on customer type, product positioning, and the custom/herd-specific vaccine thesis.
• Aptimmune Biologics: Developer of autogenous and licensed swine vaccines, now operating under Vaxxinova. Closely comparable to Genvax on target species (swine), autogenous vaccine model, and USDA-regulated biologicals pathway.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xtwitter.com/GenvaxTech
• LinkedInlinkedin.com/company/genvax

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genvax Technologies